Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07229144
PHASE1
OM336 in Seropositive Autoimmune Diseases
Sponsor: Ouro Medicines
View on ClinicalTrials.gov
Summary
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Official title: An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2025-10-01
Completion Date
2028-03
Last Updated
2026-06-15
Healthy Volunteers
No
Interventions
DRUG
OM336
OM336 is an engineered bispecific antibody directed against BCMA and CD3
Locations (1)
Waikato Hospital
Hamilton, Waikato Region, New Zealand